| Dr Robert Zesut, DO MPH | |
|
26400 Kuykendahl Rd Ste 157, The Woodlands, TX 77375-2882 | |
| (832) 422-5466 | |
| Not Available |
| Full Name | Dr Robert Zesut |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 16 Years |
| Location | 26400 Kuykendahl Rd Ste 157, The Woodlands, Texas |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295049856 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | N5507 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doctors Hospital | Augusta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Urgent Care Associates Of Texas Pllc | 1355665795 | 23 |
| Gulf Coast Emergency Physicians, Pllc | 6204280480 | 95 |
| Acs Primary Care Physicians - Southeast Pc | 5193620714 | 323 |
News Archive
A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.
An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.
StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 3 days ago
| Entity Name | Jefferson Emergency Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497966949 PECOS PAC ID: 8325130925 Enrollment ID: O20070828000367 |
News Archive
A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.
An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.
StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 3 days ago
| Entity Name | Jasper Emergency Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346442746 PECOS PAC ID: 7618062241 Enrollment ID: O20070927000597 |
News Archive
A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.
An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.
StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 3 days ago
| Entity Name | Woodlands Lone Star Emergency Physicians Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679994941 PECOS PAC ID: 5294057444 Enrollment ID: O20141125002147 |
News Archive
A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.
An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.
StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 3 days ago
| Entity Name | The Urgent Care Associates Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235539933 PECOS PAC ID: 1355665795 Enrollment ID: O20150113002159 |
News Archive
A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.
An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.
StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 3 days ago
| Entity Name | Guadalupe Emergency Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114425220 PECOS PAC ID: 0941561781 Enrollment ID: O20180219001747 |
News Archive
A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.
An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.
StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 3 days ago
| Entity Name | Gulf Coast Emergency Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972286920 PECOS PAC ID: 6204280480 Enrollment ID: O20230921001356 |
News Archive
A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.
An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.
StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 3 days ago
| Entity Name | Jasper Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922781970 PECOS PAC ID: 9133573983 Enrollment ID: O20230927001797 |
News Archive
A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.
An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.
StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 3 days ago
| Entity Name | Jefferson Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609559699 PECOS PAC ID: 4880048560 Enrollment ID: O20230928003491 |
News Archive
A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.
An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.
StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Zesut, DO MPH 26400 Kuykendahl Rd Ste 157, The Woodlands, TX 77375-2882 Ph: (360) 473-6296 | Dr Robert Zesut, DO MPH 26400 Kuykendahl Rd Ste 157, The Woodlands, TX 77375-2882 Ph: (832) 422-5466 |
News Archive
A clinical study is underway at Nyack Hospital to evaluate the use of cellphone-based technology to monitor medication adherence in discharged heart failure patients. The study is using the eMedonline telemonitoring system developed by Leap of Faith Technologies to help patients transition from the inpatient to outpatient setting.
An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.
StemCells, Inc. announced today that newly published independent research demonstrates that its GS2-M cell culture media formulation enhances the pluripotency of human embryonic stem and induced pluripotent stem cells. The Company's GS2-M medium has already been shown to enable the derivation and long-term maintenance of mouse iPS cells.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 3 days ago
Walter Kane, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 11 Hammock Dunes Pl, The Woodlands, TX 77389 Phone: 713-302-1377 | |
Dr. Michael Van Nguyen, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9250 Pinecroft Drive, The Woodlands, TX 77380 Phone: 269-337-4400 Fax: 281-364-2535 | |
Todd August, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 9250 Pinecroft Dr, The Woodlands, TX 77380 Phone: 281-364-2300 | |
Yana Gelman, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 17200 St Lukes Way, The Woodlands, TX 77384 Phone: 936-266-3900 | |
Tarannum Fatima, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 17600 Interstate 45 S, The Woodlands, TX 77384 Phone: 936-267-5000 | |
Dr. David Charles Carlyle, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2910 Laurel Cherry Way, The Woodlands, TX 77380 Phone: 281-367-3142 Fax: 281-298-1185 | |
Dr. Jamal Rahman Rahimi, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 431 Nursery Rd Ste A100, The Woodlands, TX 77380 Phone: 832-452-5840 |